783 related articles for article (PubMed ID: 12820960)
1. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
Li Y; Inoki K; Guan KL
Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
Shah OJ; Wang Z; Hunter T
Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
[TBL] [Abstract][Full Text] [Related]
5. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
6. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
Inoki K; Li Y; Xu T; Guan KL
Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
[TBL] [Abstract][Full Text] [Related]
7. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
8. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
[TBL] [Abstract][Full Text] [Related]
9. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
10. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
11. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
[TBL] [Abstract][Full Text] [Related]
13. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
Castro AF; Rebhun JF; Clark GJ; Quilliam LA
J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
[TBL] [Abstract][Full Text] [Related]
14. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis.
Shah OJ; Hunter T
Mol Cell Biol; 2006 Sep; 26(17):6425-34. PubMed ID: 16914728
[TBL] [Abstract][Full Text] [Related]
15. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
[TBL] [Abstract][Full Text] [Related]
16. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.
Yang Q; Inoki K; Kim E; Guan KL
Proc Natl Acad Sci U S A; 2006 May; 103(18):6811-6. PubMed ID: 16627617
[TBL] [Abstract][Full Text] [Related]
17. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
Robb VA; Astrinidis A; Henske EP
Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
[TBL] [Abstract][Full Text] [Related]
18. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
[TBL] [Abstract][Full Text] [Related]
19. Rheb fills a GAP between TSC and TOR.
Manning BD; Cantley LC
Trends Biochem Sci; 2003 Nov; 28(11):573-6. PubMed ID: 14607085
[TBL] [Abstract][Full Text] [Related]
20. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.
Huang J; Manning BD
Biochem J; 2008 Jun; 412(2):179-90. PubMed ID: 18466115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]